Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

28.00 

0.00 0.0%

as of Oct 04 '22

52 Week Range:

27.15 39.84


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. It offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Seprafilm, a semitransparent film-type absorbable adhesion barrier, which is applied to damaged tissue; Fiblast, a spray-on drug for the treatment of pressure ulcers and other skin ulcers; Regroth, a medicinal product for periodontal regeneration; and Hernicore for the treatment of lumbar disc herniation. The company also provides Adofeed, a pain- and inflammation-relieving plaster; Ebrantil for the treatment of dysuria and hypertension; Procylin, an oral-use prostaglandin I2 analog; Lipidil, an anti-hyperlipidemia agent; Mentax, an anti-trichophyton agent; and Loxoprofen Na Tape, a pain-relieving and anti-inflammatory plaster. In addition, it offers Ropion, a pain relief injection; and agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone, a rice herbicide; and Salinomycin, an anti-coccidial feed additive for chicken. Further, the company is developing BBI-4000 that has completed phase III clinical trial for primary axillary hyperhidrosis; KMW-1, which is in phase III clinical trial for the removal of eschar with thermal burns; KAR for treatment of hide lice infestation; and KP-607, which is in phase II clinical trial for the treatment of onychomycosis. Additionally, it is involved in the rental of Bunkyo Green Court, a commercial complex. The company offers its products under the Mentax Lotrimin Ultra, Mentax Butena, Mentax, Kaifen, Fiblast, and Jublia brands. It has license agreements with Corbus Pharmaceuticals Holdings, Inc. and Arbor Pharmaceuticals, LLC. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Earnings BIT 15,873.00
20,631.00
35,148.00
30,707.00
27,497.00
24,592.00
26,512.00
17,788.00
17,065.00
growth rate 30.0% 70.4% -12.6% -10.5% -10.6% 7.8% -32.9% -4.1%
Avg.PE 9.56
9.56
growth rate 0.0%
ROA 8.14
8.40
9.04
10.94
17.04
16.43
13.25
11.53
12.34
8.35
growth rate 3.2% 7.6% 21.0% 55.8% -3.6% -19.4% -13.0% 7.0% -32.3%
ROE 13.53
13.98
14.46
16.70
25.33
22.87
17.59
15.13
15.52
10.13
growth rate 3.3% 3.4% 15.5% 51.7% -9.7% -23.1% -14.0% 2.6% -34.7%
ROIC 11.93
12.38
13.22
15.65
23.83
21.87
16.99
14.65
15.06
9.85
growth rate 3.8% 6.8% 18.4% 52.3% -8.2% -22.3% -13.8% 2.8% -34.6%
Cur. Ratio 1.74
1.76
2.09
2.27
2.63
3.77
3.35
3.76
5.00
5.34
growth rate 1.2% 18.8% 8.6% 15.9% 43.4% -11.1% 12.2% 33.0% 6.8%
Quick Ratio 1.37
1.37
1.53
1.74
2.11
3.00
2.74
3.22
4.39
4.60
growth rate 0.0% 11.7% 13.7% 21.3% 42.2% -8.7% 17.5% 36.3% 4.8%
Leverage 1.69
1.64
1.56
1.49
1.48
1.32
1.34
1.29
1.23
1.20
growth rate -3.0% -4.9% -4.5% -0.7% -10.8% 1.5% -3.7% -4.7% -2.4%
Balance Sheet Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Acct.Receivable 25,361.00
28,204.00
29,868.00
28,231.00
33,315.00
30,340.00
21,800.00
20,549.00
20,260.00
growth rate 11.2% 5.9% -5.5% 18.0% -8.9% -28.2% -5.7% -1.4%
Acct.Payable 13,713.00
12,295.00
12,256.00
11,161.00
13,452.00
12,258.00
8,682.00
8,569.00
5,939.00
growth rate -10.3% -0.3% -8.9% 20.5% -8.9% -29.2% -1.3% -30.7%
Cur.Assets 58,501.00
69,016.00
88,991.00
90,494.00
105,055.00
103,731.00
108,336.00
113,662.00
110,613.00
growth rate 18.0% 28.9% 1.7% 16.1% -1.3% 4.4% 4.9% -2.7%
Total Assets 106,465.00
115,135.00
132,991.00
135,060.00
152,417.00
155,985.00
157,875.00
163,332.00
165,181.00
growth rate 8.1% 15.5% 1.6% 12.9% 2.3% 1.2% 3.5% 1.1%
Cash 9,644.00
10,553.00
29,845.00
33,867.00
45,095.00
46,956.00
59,722.00
63,706.00
61,025.00
growth rate 9.4% 182.8% 13.5% 33.2% 4.1% 27.2% 6.7% -4.2%
Inventory 13,220.00
13,482.00
14,506.00
16,495.00
16,651.00
13,719.00
12,274.00
15,197.00
14,980.00
growth rate 2.0% 7.6% 13.7% 1.0% -17.6% -10.5% 23.8% -1.4%
Cur.Liabilities 28,056.00
30,369.00
33,861.00
24,020.00
31,401.00
27,580.00
21,655.00
21,276.00
19,049.00
growth rate 8.2% 11.5% -29.1% 30.7% -12.2% -21.5% -1.8% -10.5%
Liabilities 38,370.00
38,036.00
43,117.00
32,406.00
38,543.00
34,855.00
29,407.00
27,075.00
26,857.00
growth rate -0.9% 13.4% -24.8% 18.9% -9.6% -15.6% -7.9% -0.8%
Equity 68,095.00
77,099.00
89,874.00
102,654.00
113,874.00
121,130.00
128,468.00
136,257.00
137,746.00
growth rate 13.2% 16.6% 14.2% 10.9% 6.4% 6.1% 6.1% 1.1%
Common Shares 45.00
44.00
43.00
42.00
41.00
41.00
23,853.00
23,853.00
23,853.00
23,853.00
23,853.00
growth rate -2.2% -2.3% -2.3% -2.4% 0.0% 58,078.1% 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Capital Expenditures 2,071.00
1,954.00
3,124.00
2,166.00
1,689.00
1,908.00
2,159.00
1,973.00
2,986.00
growth rate -5.7% 59.9% -30.7% -22.0% 13.0% 13.2% -8.6% 51.3%
Cash Dividends 3,936.00
4,263.00
5,463.00
6,288.00
6,085.00
6,001.00
5,896.00
5,811.00
5,714.00
growth rate 8.3% 28.2% 15.1% -3.2% -1.4% -1.8% -1.4% -1.7%
Cash From OA 13,663.00
14,737.00
27,067.00
15,327.00
21,703.00
21,129.00
27,468.00
14,380.00
13,336.00
growth rate 7.9% 83.7% -43.4% 41.6% -2.6% 30.0% -47.7% -7.3%
FCF 7,756.00
7,815.00
11,537.00
12,709.00
23,850.00
12,973.00
19,815.00
19,001.00
25,266.00
12,094.00
10,350.00
growth rate 0.8% 47.6% 10.2% 87.7% -45.6% 52.7% -4.1% 33.0% -52.1% -14.4%
Income Statement Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18 Mar '19 Mar '20 Mar '21 Mar '22
Sales 88,946.00
93,889.00
109,730.00
101,479.00
98,430.00
94,165.00
89,232.00
74,979.00
76,034.00
growth rate 5.6% 16.9% -7.5% -3.0% -4.3% -5.2% -16.0% 1.4%
Op.Income 15,873.00
20,631.00
35,148.00
30,707.00
27,497.00
24,592.00
26,512.00
17,788.00
17,065.00
growth rate 30.0% 70.4% -12.6% -10.5% -10.6% 7.8% -32.9% -4.1%
IBT 15,496.00
18,610.00
35,291.00
31,092.00
27,686.00
24,922.00
26,592.00
18,657.00
13,885.00
growth rate 20.1% 89.6% -11.9% -11.0% -10.0% 6.7% -29.8% -25.6%
Net Income 9,735.00
12,122.00
21,143.00
22,017.00
19,043.00
17,775.00
19,370.00
13,405.00
9,549.00
growth rate 24.5% 74.4% 4.1% -13.5% -6.7% 9.0% -30.8% -28.8%
EPS 184.92
206.60
228.28
290.90
510.54
536.70
470.54
445.78
494.89
347.37
growth rate 11.7% 10.5% 27.4% 75.5% 5.1% -12.3% -5.3% 11.0% -29.8%
Gross Profit 43,780.00
49,135.00
61,638.00
57,452.00
56,027.00
53,801.00
50,481.00
40,906.00
41,576.00
growth rate 12.2% 25.5% -6.8% -2.5% -4.0% -6.2% -19.0% 1.6%
R&D 7,045.00
7,615.00
5,883.00
6,450.00
8,152.00
10,261.00
6,418.00
6,736.00
8,420.00
growth rate 8.1% -22.7% 9.6% 26.4% 25.9% -37.5% 5.0% 25.0%

Quarterly Statements

Item Name Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Earnings BIT 2,839.00
4,422.00
4,615.00
4,853.00
3,175.00
growth rate 55.8% 4.4% 5.2% -34.6%
Balance Sheet Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Acct.Receivable 20,549.00
20,583.00
20,728.00
26,737.00
20,260.00
growth rate 0.2% 0.7% 29.0% -24.2%
Acct.Payable 8,569.00
8,603.00
7,162.00
7,978.00
5,939.00
growth rate 0.4% -16.8% 11.4% -25.6%
Cur.Assets 113,662.00
112,651.00
114,868.00
111,519.00
110,613.00
growth rate -0.9% 2.0% -2.9% -0.8%
Total Assets 163,332.00
163,340.00
165,591.00
167,677.00
165,181.00
growth rate 0.0% 1.4% 1.3% -1.5%
Cash 63,706.00
60,924.00
62,670.00
53,363.00
61,025.00
growth rate -4.4% 2.9% -14.9% 14.4%
Inventory 15,197.00
16,878.00
17,177.00
16,919.00
14,980.00
growth rate 11.1% 1.8% -1.5% -11.5%
Cur.Liabilities 21,276.00
21,592.00
21,272.00
22,073.00
19,049.00
growth rate 1.5% -1.5% 3.8% -13.7%
Liabilities 27,075.00
27,642.00
27,261.00
27,986.00
26,857.00
growth rate 2.1% -1.4% 2.7% -4.0%
Equity 136,257.00
135,698.00
138,330.00
139,113.00
137,746.00
growth rate -0.4% 1.9% 0.6% -1.0%
Common Shares 23,853.00
23,853.00
23,853.00
23,853.00
23,853.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Income Statement Mar '21 Jun '21 Sep '21 Dec '21 Mar '22
Sales 17,897.00
18,453.00
19,135.00
20,120.00
18,326.00
growth rate 3.1% 3.7% 5.2% -8.9%
Op.Income 2,839.00
4,422.00
4,615.00
4,853.00
3,175.00
growth rate 55.8% 4.4% 5.2% -34.6%
IBT 2,975.00
4,654.00
4,781.00
5,022.00
-572.00
growth rate 56.4% 2.7% 5.0% -100.0%
Net Income 2,471.00
3,362.00
3,359.00
3,525.00
-697.00
growth rate 36.1% -0.1% 4.9% -100.0%
Gross Profit 9,104.00
10,276.00
10,724.00
11,019.00
9,557.00
growth rate 12.9% 4.4% 2.8% -13.3%
R&D 1,874.00
1,865.00
2,143.00
2,027.00
2,385.00
growth rate -0.5% 14.9% -5.4% 17.7%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (0.00)

YOY Growth Grade:

E (32.58)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 8.02 8.02
EPS / Growth 3.49

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 5.7%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 5.7% 5.7% 5.7%
Future PE 0.01 6.44 6.44
Future EPS 6.05 6.05 6.05
Value Price
MOS %
0.02
-99.9%
9.63
-65.6%
9.63
-65.6%
MOS Price 0.01 4.82 4.82
IRT 6.49 6.49 6.49

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.